Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide

• US 8,916,199 B1
• Filed: 07/14/2011
• Issued: 12/23/2014
• Est. Priority Date: 04/25/2008
• Status: Expired due to Fees

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic), University of Central Florida Research Foundation Inc. (State University System of Florida)
• Original Assignee: University of Central Florida Research Foundation IND
• Inventors: Seal, Sudipta, Karakoti, Ajay, Shridhar, Vijayalakshmi, Giri, Shailendra
• Primary Examiner(s): Justice, Gina C
• Assistant Examiner(s): Alley, Genevieve S
• Application Number:
  US13/182,522
• Time in Patent Office: 1,258 Days
• Field of Search: 424/489
• US Class Current: 424/489
• CPC Class Codes: A61K 33/244 Lanthanides; Compounds thereof medicinal preparations containing radioactive lanthanides for use in therapy or testing in vivo A61K51/00
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51

Abstract

The invention provides a method of treating ovarian cancer in a mammal, the method inhibits angiogenesis associated with the cancer and comprises the parenteral administration to the mammal of an effective amount of cerium oxide nanoparticles having a predominance of Ce⁺³.

Claims

1. A method of treating ovarian cancer in a mammal, the method comprising parenteral administration to the mammal of an effective amount of cerium oxide in nanoparticles having a predominance of Ce⁺³.

2. The method of claim 1, wherein the mammal is a human subject.

3. The method of claim 1, wherein parenteral administration comprises intraperitoneal administration.

4. The method of claim 1, wherein the effective amount comprises less than approximately 1 mg per kilogram of body weight of the mammal.

5. The method of claim 1, wherein the effective amount comprises approximately 0.1 mg per kilogram of body weight of the mammal.

6. The method of claim 1, wherein the effective amount is parenterally administered approximately every 72 hours.

7. A method of inhibiting growth-mediated cell migration and invasion of mammalian ovarian cancer cells, the method comprising contacting the cells with an effective amount of cerium oxide nanoparticles having a predominance of Ce⁺³.

8. A method of inhibiting angiogenesis associated with a mammalian ovarian carcinoma, the method comprising contacting the carcinoma with an effective amount of cerium oxide nanoparticles having a predominance of Ce⁺³.

9. The method of claim 8, wherein contacting the carcinoma further comprises contacting vascular endothelial cells associated with the carcinoma.